Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Epoprostenol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGIR known ✓ | P43119 | 6/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.98 |
| ▸ | MEN1 | O00255 | 2/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.70 |
| ▸ | PPARG | P37231 | 1/20 | 0.70 |
| ▸ | PPARD | Q03181 | 1/20 | 0.70 |
| ▸ | PPARA | Q07869 | 1/20 | 0.70 |
| ▸ | PTGER4 | P35408 | 4/20 | 0.56 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.56 |
| ▸ | PTGFR | P43088 | 2/20 | 0.56 |
| ▸ | PTGER3 | P43115 | 2/20 | 0.56 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.56 |
| ▸ | SLCO2A1 | Q92959 | 1/20 | 0.56 |
| ▸ | PTGER2 | P43116 | 3/20 | 0.55 |
| ▸ | TSHR | P16473 | 3/20 | 0.55 |
| ▸ | HPGD | P15428 | 3/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.55 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Epoprostenol SCHEMBL41345 | 1.00 | ALDH1A1 (0.98) | ALDH1A1MEN1KMT2APPARGPPARD | |
| Epoprostenol SCHEMBL705594 | 0.99 | ALDH1A1 (1.00) | ALDH1A1MEN1KMT2APPARGPPARD | |
| Epoprostenol SCHEMBL22607961 | 0.99 | ALDH1A1 (1.00) | ALDH1A1MEN1KMT2APPARGPPARD | |
| Epoprostenol SCHEMBL551616 | 0.99 | ALDH1A1 (1.00) | ALDH1A1MEN1KMT2APPARGPPARD | |
| Epoprostenol SCHEMBL24612535 | 0.99 | ALDH1A1 (1.00) | ALDH1A1MEN1KMT2APPARGPPARD | |
| Epoprostenol SCHEMBL24033081 | 0.99 | ALDH1A1 (1.00) | ALDH1A1MEN1KMT2APPARGPPARD | |
| Epoprostenol SCHEMBL4165739 | 0.99 | ALDH1A1 (1.00) | ALDH1A1MEN1KMT2APPARGPPARD | |
| Epoprostenol SCHEMBL24340812 | 0.99 | ALDH1A1 (1.00) | ALDH1A1MEN1KMT2APPARGPPARD | |
| Epoprostenol SCHEMBL21283002 | 0.99 | ALDH1A1 (1.00) | ALDH1A1MEN1KMT2APPARGPPARD | |
| Epoprostenol SCHEMBL16783375 | 0.99 | ALDH1A1 (1.00) | ALDH1A1MEN1KMT2APPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117887421-A | Ultrahigh-heat-conductivity graphene foam energy storage material and preparation method thereof | 中国空间技术研究院 | 2024-04-16 | — | — | CN | claimed |
| CN-107325122-B | Novel intermediate for preparing prostaglandins and preparation method thereof | 常州博海威医药科技股份有限公司 | 2020-05-01 | — | — | CN | claimed |
| US-20040072846-A1 | Pharmaceutical formulation containing thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives | MERCK PATENT GMBH (DE) | 2004-04-15 | — | — | US | claimed |
| US-20040063730-A1 | Pharmacuetical formulation comprising puyrazolo[4,-3-d]pyrimidines and antithrombotics, calcium antagonists, or prostaglandins or prostaglandin derivatives | MERCK PATENT GMBH (DE) | 2004-04-01 | — | — | US | claimed |
| US-20040058940-A1 | Pharmaceutical formulation comprising thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives (2) | MERCK PATENT GMBH (DE) | 2004-03-25 | — | — | US | claimed |
| US-4404212-A | ADMINISTERING ALONG WITH A HYDROLASE INHIBITOR; ANTICOAGULANTS | BURROUGHS WELLCOME CO. (US) | 1983-09-13 | — | — | US | claimed |
| US-4393063-A | SYNERGISTIC COMBINATION OF LA PROSTACYCLINE AND A PHOSPHODIESTERASE INHIBITOR | BURROUGHS WELLCOME CO. (US) | 1983-07-12 | — | — | US | claimed |
| US-4337254-A | ANTICOAGULANTS COMPRISING A PROSTACYCLIN AND A PHOSPHODIESTERASE INHIBITOR; PREVENTING LOWERING OF BLOOD PRESSURE | BURROUGHS WELLCOME CO. (US) | 1982-06-29 | — | — | US | claimed |
| CN-117887421-A | Ultrahigh-heat-conductivity graphene foam energy storage material and preparation method thereof | 中国空间技术研究院 | 2024-04-16 | — | — | CN | disclosed |
| CN-117338789-A | Compound sildenafil citrate and prostacyclin sodium sustained release preparation and preparation method thereof | 北京尚修堂医药科技有限公司 | 2024-01-05 | — | — | CN | disclosed |
| CN-117338789-A | Compound sildenafil citrate and prostacyclin sodium sustained release preparation and preparation method thereof | 北京尚修堂医药科技有限公司 | 2024-01-05 | — | — | CN | disclosed |
| CN-117338789-A | Compound sildenafil citrate and prostacyclin sodium sustained release preparation and preparation method thereof | 北京尚修堂医药科技有限公司 | 2024-01-05 | — | — | CN | disclosed |
| CN-109153660-B | Method for preparing epoprostenol sodium with enhanced stability | 奇诺因药物和化学工厂私人有限公司 | 2022-10-11 | — | — | CN | disclosed |
| CN-114668764-A | Application of compound in preparation of external medicine for treating diabetic foot | 中南大学 | 2022-06-28 | — | — | CN | disclosed |
| US-4404212-A | ADMINISTERING ALONG WITH A HYDROLASE INHIBITOR; ANTICOAGULANTS | BURROUGHS WELLCOME CO. (US) | 1983-09-13 | — | — | US | disclosed |
| EP-0005768-B1 | PHARMACEUTICAL FORMULATIONS CONTAINING PROSTAGLANDIN COMPOUNDS AND METHOD FOR THEIR PREPARATION | THE WELLCOME FOUNDATION LIMITED (GB) | 1983-08-10 | — | — | EP | disclosed |
| US-4393063-A | SYNERGISTIC COMBINATION OF LA PROSTACYCLINE AND A PHOSPHODIESTERASE INHIBITOR | BURROUGHS WELLCOME CO. (US) | 1983-07-12 | — | — | US | disclosed |
| US-4337254-A | ANTICOAGULANTS COMPRISING A PROSTACYCLIN AND A PHOSPHODIESTERASE INHIBITOR; PREVENTING LOWERING OF BLOOD PRESSURE | BURROUGHS WELLCOME CO. (US) | 1982-06-29 | — | — | US | disclosed |
| US-4335139-A | PROSTAGLANDINS | BURROUGHS WELLCOME CO. (US) | 1982-06-15 | — | — | US | disclosed |
| EP-0005768-A1 | Pharmaceutical formulations containing prostaglandin compounds and method for their preparation | THE WELLCOME FOUNDATION LIMITED (GB) | 1979-12-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072846-A1 | Pharmaceutical formulation containing thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives | PTGER1, TBXA2R, PTGIS | PTGIR 4/4885ALDH1A1 2919/4885MEN1 1560/4885 |
| US-20040063730-A1 | Pharmacuetical formulation comprising puyrazolo[4,-3-d]pyrimidines and antithrombotics, calcium antagonists, or prostaglandins or prostaglandin derivatives | PTGIS, PTGIR, PTGER1 | PTGIR 2/4885ALDH1A1 1618/4885MEN1 3198/4885 |
| US-20040058940-A1 | Pharmaceutical formulation comprising thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives (2) | PTGER1, PTGIS, PTGIR | PTGIR 3/4885ALDH1A1 1756/4885MEN1 1895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.